Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Antibe Therapeutics Inc (ATE.TO)

Antibe Therapeutics Inc (ATE.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results

Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its financial and...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)
Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions,...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions,...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)
Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions,...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)
Antibe Therapeutics Announces Results of 2021 Annual Meeting

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)
Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results

Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its financial and...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)
Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions,...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)
Antibe Therapeutics Provides Clinical Update for Otenaproxesul

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has placed its absorption,...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)
Antibe Therapeutics Provides July 2021 Corporate Update

Antibe Therapeutics Inc.:

ATE.TO : 0.69 (-8.00%)
Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today filed its financial...

ATE.TO : 0.69 (-8.00%)
ATBPF : 0.5558 (-5.80%)

Barchart Exclusives

Can Lumber Trade At $2,000?
Few markets have been as volatile as lumber over the past years. In 2021, the price of nearby wood futures traded as high as over $1700 and as low as below $500 per 1,000 board feet. In early 2022, it looks like the extreme price variance in the lumber futures arena will continue, and the price could reach $2,000 or higher in the illiquid market. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar